primary structure [cyclo-(Val-Orn-Leu-D-Phe-Pro) 2 ] (1). GS is an extremely powerful antibiotic drug against a broad spectrum of both Gram-negative and Gram-positive bacteria and against several pathogenic fungi (2-5). GS-deficient mutants in Aneurinibacillus migulanus have been classified into five different categories. The mutant E1 belongs to the fifth group that contains both a phenylalanine-activating enzyme and a complex of proline-, valine-, ornithine-, and leucineactivating enzymes similar to those of the wild-type strain (6) . E1 is unable to synthetize GS or D-phenylalanyl-L-propyl diketopiperazine (DKP).
The genome of the A. migulanus E1 mutant was sequenced by the Illumina HiSeq 2000 platform (2 ϫ 125 bp), and the sequencing coverage was 100ϫ. After sequencing, the reads were assembled using CLC Genomics Workbench 7.0.3 (CLC bio). Annotation was performed using the NCBI Prokaryotic Genomes Automatic Annotation Pipeline (PGAAP) version 2.9 (7) . The whole genome is represented by a circular chromosome of 6,301,904 bp with no plasmid. The GϩC content was around 43.20%, as reported for other Aneurinibacillus species (2, 3). The genome contains 5,672 coding sequences (CDSs), 11 rRNA operons, and 95 tRNA genes. Using anti-SMASH 3.0, 12 gene clusters for secondary metabolites have been predicted in the genome of the E1 A. migulanus mutant strain (8) . Nonribosomal peptides, terpenes, polyketides, siderophores, bacteriocins, microcins, lasso peptides, and arylpolyene are among the predicted secondary metabolites. This suggests an important structural diversity of E1 secondary metabolites. The availability of the genome sequence of the E1 mutant is supposed to help identify mutations in this gramici-din S-deficient mutant and therefore to understand the genetic regulation of gramicidin S biosynthesis in A. migulanus.
Nucleotide sequence accession number. The sequence of the E1 chromosome has been deposited in GenBank under accession the no. LIXL00000000. The version described in this paper is the first version.
